Neovacs SA (France) Today
| ALNEV Stock | EUR 0.0002 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 71
|
Neovacs SA is selling at 2.0E-4 as of the 21st of November 2024; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 2.0E-4. Neovacs SA has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Neovacs SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. Neovacs S.A. was founded in 1993 and is based in Paris, France. NEOVACS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. The company has 590.99 M outstanding shares. More on Neovacs SA
Moving against Neovacs Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Neovacs Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Neovacs SA's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Neovacs SA or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Neovacs SA (ALNEV) is traded on Euronext Paris in France and employs 21 people. The company currently falls under 'Nano-Cap' category with a current market capitalization of 531.89 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neovacs SA's market, we take the total number of its shares issued and multiply it by Neovacs SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Neovacs SA operates under Biotechnology sector and is part of Health Care industry. The entity has 590.99 M outstanding shares.
Neovacs SA has accumulated about 1.42 M in cash with (9.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Neovacs SA Probability Of Bankruptcy
Neovacs SA Risk Profiles
Although Neovacs SA's alpha and beta are two of the key measurements used to evaluate Neovacs SA's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 11.0 | |||
| Standard Deviation | 18.24 | |||
| Variance | 332.59 | |||
| Risk Adjusted Performance | (0.07) |
Neovacs Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Neovacs SA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Neovacs SA Corporate Management
Elected by the shareholders, the Neovacs SA's board of directors comprises two types of representatives: Neovacs SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neovacs. The board's role is to monitor Neovacs SA's management team and ensure that shareholders' interests are well served. Neovacs SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neovacs SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexandre Courtoux | Adm Director | Profile | |
| Pr Zagury | Chairman Founder | Profile | |
| Valerie Salentey | Head of Regulatory Affairs | Profile | |
| Hugo Brugiere | GM Chairman | Profile | |
| Charlene Masson | Co Relations | Profile | |
| Vincent Serra | Chief Scientific Officer | Profile |
Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.